Current Medicines for Malaria Including Resistance Issues
Dejen Nureye1★, Mohammed Salahaddin1,2, Ameha Zewudie1★ Corresponding author
- 1Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Aman Campus, Mizan-Aman, Ethiopia.
- 2Department of Biomolecular Sciences, Pharmacology Division, University of Mississippi, Mississippi, United States of America.
CORRESPONDENCE
Dejen Nureye
Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Aman Campus, P.O. Box 260, Southwest, Mizan-Aman, Ethiopia.
Received: 28-02-2020; Revised: 22-09-2020; Accepted: 03-10-2020.
Volume 11, Issue 3 · pp. 90–99 · PUBLISHED 23 December 2020 · DOI: 10.4103/jpp.JPP_23_20
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Malaria is an old disease and continues to be a major health problem in many countries. In spite of decrement in morbidity and mortality due to malaria, the transmission is still active throughout the world. Hence, appropriate treatment is needed to handle malaria in addition to preventive measures. However, unavailability of new drugs and the occurrence of resistant Plasmodium strains toward many conventional antimalarial drugs including artemisinins are the major obstacles in combating malaria infection. Thus, experts from all directions of our planet are in search of novel compounds, and many new chemical entities, such as artefenomel, ferroquine, KAE609, KAF156, DSM265, methylene blue, MMV39048, DDD107498, SJ733, and MMV253, have been under drug development process. While many agents are in the pipeline, most of them are not able to kill both gametocytes and hypnozoites.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Nureye, D., Salahaddin, M., & Zewudie, A. (2020). Current Medicines for Malaria Including Resistance Issues. Journal of Pharmacology and Pharmacotherapeutics, 11(3), 90–99. https://doi.org/10.4103/jpp.JPP_23_20